


1. PRODUCT AND COMPANY INFORMATION

Distributed By: WG Critical Care, LLC.
120 Route 17 North
Suite 115
Paramus, NJ 07652 USA

Product Name: **CEFOXITIN FOR INJECTION, USP**

Active Ingredient/Primary Component: CEFOXITIN SODIUM

Structure:



Chemical Name: (1) 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-, sodium salt, (6*R*-*cis*)-; (2) Sodium (6*R*,7*S*)-3-(hydroxymethyl)-7-methoxy-8-oxo-7-[2-(2-thienyl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate carbamate (ester)

Molecular Formula: C₁₆H₁₆N₃NaO₇S₂
UNII Code: UNII-Q68050H03T
CAS Number: CAS-33564-30-6
Chemical Family: Antibacterial
Product Use: Pharmaceutical
Product Type: Prescription Drug

Container Information: Vials

WG Critical Care, LLC.

Cefoxitin for Injection, USP	Safety Data Sheet (SDS)		
Version: 2.3	Issue Date: June 18, 2015		Page 1 of 6



1. PRODUCT AND COMPANY INFORMATION (CONT.)

General Phone +1-847-549-3200
Number:
 Customer Service +1-888-493-0861
Phone Number:
 Emergency Phone +1-866-562-4708 (Prosar)
Number:

2. HAZARDS IDENTIFICATION

PRIMARY PHYSICAL AND HEALTH HAZARDS: Do not ingest. Avoid eye contact. May cause skin and eye irritation. May cause allergic reactions.

ROUTES OF ENTRY: Inhalation, eye/skin contact, or ingestion

SIGNS & SYMPTOMS OF EXPOSURE: Potential adverse reactions can happen from prescribed and overdoses are prescribed in the package insert. Side effects may include: allergic reactions, hypotension, gastrointestinal, neuromuscular, renal, and / or hepatic abnormalities.

CHEMICAL LISTED AS CARCINOGEN: **NTP: NO** **IARC: NO** **OSHA: NO**

3. COMPOSITION / INFORMATION ON INGREDIENTS

<u>Ingredient</u>	<u>Weight %</u>	<u>CAS No.</u>
Cefoxitin Sodium	100	33564-30-6

4. FIRST AID MEASURES

EYE EXPOSURE: Immediately flush eyes with water for at least 15 minutes. Seek medical attention.

SKIN EXPOSURE: Remove contaminated clothing immediately. Flush area with water for at least 15 minutes. Seek medical attention.

INGESTION: Flush mouth out with water immediately. Seek medical attention.

INHALATION: Move exposed subject to fresh air immediately. Give artificial respiration and cardiopulmonary resuscitation (CPR) if required. Seek medical attention.

NOTE TO PHYSICIAN: See patient package insert in shipping carton for complete information.

WG Critical Care, LLC.

Cefoxitin for Injection, USP	Safety Data Sheet (SDS)		
Version: 2.3	Issue Date: June 18, 2015		Page 2 of 6



5. FIRE FIGHTING MEASURES

FLASH POINT:	Not Determined
AUTO-IGNITION TEMPERATURE:	Not Available
FLAMMABLE LIMITS IN AIR:	Not Available
FLAMMABLE LIMITS:	Not Available
EXTINGUISHING MEDIA:	Use foam or an all purpose dry chemical to extinguish
UNUSUAL FIRE / EXPLOSION HAZARDS:	No Information Available

6. ACCIDENTAL RELEASE MEASURE

PERSONAL PRECAUTIONS:	Wear positive pressure self-contained breathing apparatus and full turnout gear.
RELEASE TO AIR:	No Information Available
RELEASE TO WATER:	No Information Available

7. HANDLING AND STORAGE

GENERAL HANDLING:	When handling pharmaceutical products, avoid all contact and inhalation of dust, fumes, mist, and/or vapors associated with the product. This material has not been tested for its dust explosion properties. However, like most organic dusts, it is expected to explode when ignited as a dust cloud. Care should be taken to avoid dispersion as a dust cloud.
STORAGE CONDITIONS:	Store at 2° - 25 °C (36° - 77° F) the final dosage form. Avoid exposure to temperatures above 50°C.

WG Critical Care, LLC.

Cefoxitin for Injection, USP	Safety Data Sheet (SDS)		
Version: 2.3	Issue Date: June 18, 2015		Page 3 of 6



8. EXPOSURE CONTROLS / PERSONAL PROTECTION

RESPIRATORY PROTECTION: With satisfactory ventilation, respiratory protection is usually not required.

EYE PROTECTION: Safety glasses or goggles recommended

VENTILATION General room ventilation is usually satisfactory. Use local exhaust ventilation if necessary.

SKIN PROTECTION: Disposable latex gloves recommended. Disposable garments if direct skin contact is anticipated

OTHER PROTECTIVE EQUIPMENT: N/A

ADDITIONAL EXPOSURE PRECAUTIONS: NONE

9. PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE:	Sterile Powder	SPECIFIC GRAVITY:	Not Established
APPEARANCE AND ODOR:	White Crystalline Powder; Solutions can range from white to amber	EVAPORATION RATE:	Not Established
BOILING POINT:	Not Established	MELTING POINT:	Not Established
VAPOR PRESSURE:	Not Established	SOLUBILITY IN WATER:	Very Soluble in water
VAPOR DENSITY:	Not Established	pH:	4.2-7.0

10. STABILITY AND REACTIVITY

STABILITY: Stable under normal conditions

INCOMPATIBILITY : (MATERIALS TO AVOID) None Reported

HAZARDOUS POLYMERIZATION: Will not occur

HAZARDOUS DECOMPOSITION: Not established

CONDITIONS TO AVOID: Avoid direct sunlight and conditions that might generate heat and dispersion

WG Critical Care, LLC.

Cefoxitin for Injection, USP		Safety Data Sheet (SDS)	
Version: 2.3	Issue Date: June 18, 2015		Page 4 of 6



11. TOXICOLOGICAL INFORMATION

ACUTE TOXICITY

COMPONENT	TYPE	ROUTE	SPECIES	DOSAGE
Cefoxitin Sodium	LD ₅₀	Oral	Rat	10gm/kg

Signs & Symptoms of Exposure & Overexposure:

This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert. Side effects from therapeutic doses include: allergic reactions, hypotension, gastrointestinal neuromuscular, renal, and hepatic abnormalities. Occupational exposure has not been fully investigated.

Medical Conditions Aggravated by Accidental Exposure:

Individuals with hypersensitivity to cefoxitin and to the cephalosporin and penicillin group of antibiotics.

IMMEDIATE EFFECTS: Eye, skin, and respiratory irritation may occur. Exposure may cause allergic reactions in certain individuals and cross-allergenicity with penicillin allergic individuals.

DELAYED EFFECTS: Hypersensitivity reactions ranging from mild to life-threatening may occur.

12. ECOLOGICAL INFORMATION

No applicable ecological information found

13. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL: Treatment, storage, transportation, and disposal must be in accordance with applicable federal, state, and local regulations

14. TRANSPORT INFORMATION

REGULATORY ORGANIZATIONS:

DOT: Not Regulated

ICAO / IATA: Not Regulated

IMO: Not Regulated

WG Critical Care, LLC.

Cefoxitin for Injection, USP	Safety Data Sheet (SDS)		
Version: 2.3	Issue Date: June 18, 2015		Page 5 of 6



15. REGULATORY INFORMATION

Below is selected regulatory information chosen primarily for possible WG Critical Care use. This section is not a complete analysis or reference to all applicable regulatory information. Please consider all applicable laws and regulations for your city / state / country.

US Regulations

TSCA – No

CERCLA-No

SARA 302 – No

SARA 313 – No

OSHA Substance Specific – No

EINECS Number: 251-574-6

16. OTHER INFORMATION

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

WG Critical Care, LLC.

Cefoxitin for Injection, USP		Safety Data Sheet (SDS)	
Version: 2.3	Issue Date: June 18, 2015		Page 6 of 6